Condition: Breast Cancer · Sponsor: Genor Biopharma Co., Ltd.
The main purpose of this study is to evaluate the efficacy and safety of GB491 combined with Letrozole versus placebo combined with Letrozole in the treatment of HR+/HER2- locally advanced or metastatic breast cancer without prior systemic antitumor therapy
This description comes directly from the study's public registry record.
Yankun Fu, Master · 021-60751991 · yankun.fu@genorbio.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Bengbu Medical College | Bengbu, Anhui, China | Recruiting |
| The First Hospital of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Anhui Cancer Hospital | Hefei, Anhui, China | Recruiting |
| The Second Hosptial of Anhui Medical University | Hefei, Anhui, China | Recruiting |
| Betjing Tiantan Hosptial，Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Chinese PLA General Hospial | Beijing, Beijing Municipality, China | Recruiting |
| The First Affiliated Hospital of Chongqing Medical University | Chongqing, Chongqing Municipality, China | Recruiting |
| Chongqing University Cancer Hospital | Chongqing, Chongqing Municipality, China | Recruiting |
| Fujian Medical University Union Hospital | Fuzhou, Fujian, China | Recruiting |
| The First Hospital of Wenzhou Medical University | Wenzhou, Fujian, China | Recruiting |
| The First Affiliated Hosptial of Xiamen University | Xiamen, Fujian, China | Recruiting |
| The First People's Hospital of Foshan | Foshan, Guangdong, China | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05851014